Dr Alexandra Andrews has expertise in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments. She has worked closely with clinical researchers, investors and entrepreneurs, providing scientific and strategic input into clinical development plans, and overseeing manufacturing.
Dr Andrews became the chief executive of Neurotech International in March 2022 and transitioned to a chief operating officer in September 2022. Prior to Neurotech, she was the director of operations at NeuroScientific Biopharmaceuticals and a US client engagement specialist at Linear Clinical Research where she focused on attracting partnerships with US biotechnology and pharmaceutical companies, and managing trial logistics.
| Rank | Company | # | |
|---|---|---|---|
| 136th |  |
Neurotech International | $3.18m |
| 140th |  |
WhiteHawk | $2.64m |
| 141st | |
International Equities Corporation | $2.60m |
| 142nd | |
Argenica Therapeutics | $2.60m |
| 144th | |
Osteopore | $2.41m |
|
NEW ROLE: Chief Operating Officer, Neurotech International | 01 Sep 2022 |
|
|
NEW ROLE: Director of Operations, NeuroScientific Biopharmaceuticals | 03 Mar 2022 |
|
|
NEW ROLE: Chief Executive, Neurotech International | 03 Mar 2022 |
